A randomized, double-blind, placebo-controlled, time lagged, parallel group, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AEB071 doses greater than 500 mg in healthy subjects

Trial Profile

A randomized, double-blind, placebo-controlled, time lagged, parallel group, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AEB071 doses greater than 500 mg in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2010

At a glance

  • Drugs Sotrastaurin (Primary)
  • Indications Liver transplant rejection; Psoriasis; Renal transplant rejection; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jun 2007 Status change from in progress to completed
    • 04 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top